New immunisation reference page: Injection site nodules
Injection site nodules are a rare but known adverse event following immunisation. They can occur following any vaccine and are most commonly asymptomatic and self resolving. Our new reference page describes what injection site nodules are and the implications on future immunisations.
To learn more follow the link below:
2020年流感疫苗——现在接种还不算太晚
流感疾病可能在一年中的任何时间发生，建议 6 个月以上的每个人都接种疫苗。某些患者群体有资格获得国家免疫计划 (NIP) 资助的流感疫苗。不符合资助标准的人也可以购买。
有关 2020 年流感疫苗接种的更多信息，请参阅以下资源：
Australian Government Department of Health: 2020 influenza vaccines- it's not too late to get vaccinated
MVEC：流感疫苗建议
MVEC：流感疫苗 - 常见问题
New immunisation reference page: Melbourne immunisation drive-through clinics
Staying up to date with scheduled and additional vaccinations, remains essential during the COVID-19 pandemic. Concerning results from the Royal Children’s Hospital (RCH) National Child Health Poll, indicate the impact that the pandemic has had on immunisation, with data showing 1 in 5 children have had those vaccinations delayed since the beginning of the pandemic.
Families are reminded that it is safe and recommended to attend local immunisation providers (GP or local council) for vaccinations, however drive-through clinics are also available at Monash Health in Clayton and the RCH in Parkville.
For more information please refer to the following:
MVEC: Melbourne immunisation drive-through clinics
Zostavax safety advice: not to be administered to people with compromised immune function
The Therapeutic Goods Administration (TGA) have issued a reminder that Zostavax® vaccine should not be administered to people with compromised immune function. Vaccination in this patient group is contraindicated and can result in infection with the vaccine virus causing mild to severe complications (including death).
Further details on the alert can be seen here: TGA: Zostavax® vaccine
For more information on Zostavax® and access to the Zostavax® GP decision aid please review the MVEC pages below:
MVEC：带状疱疹
MVEC: Zoster vaccine (Zostavax®) FAQ's
New immunisation reference page: Foetal embryonic cells- utilised in vaccine development platforms
Foetal embryonic cell lines isolated in the early 1960's have been used to develop a number of various vaccines. As scientists work to produce an effective vaccine against SARS CoV-2 it is important to explore as many technologies as possible. Addressing ethical and religious concerns is an essential part of COVID-19 vaccine readiness planning. Our new reference page details the background behind the use of foetal embryonic cells and the role they play in the development of vaccines, the reasons why they are used, as well as addressing any religious and ethical implications.
To access our reference page follow the link to MVEC: Foetal embryonic cells- utilised in vaccine development platforms.
New immunisation reference page: Immunosuppression and vaccines
Having certain medical conditions or taking specific medications can lead to immunosuppression and the decreased ability to fight infections. For these patients, prevention of disease is critical. Our new reference page outlines additional vaccines to consider, and specific vaccines that may be contraindicated.
To learn more follow the link to MVEC：免疫抑制和疫苗
New immunisation reference page: Breastfeeding and immunisations
Immunising breastfeeding mothers can not only protect the mother from vaccine preventable diseases but also provide passive immunity to the baby. Our new reference page details different vaccines and scenarios for consideration when immunising a mother who is breastfeeding.
To learn more follow the link to MVEC: Breastfeeding and immunisation
New immunisation reference page: Eczema and immunisations
Eczema or atopic dermatitis is a common skin condition affecting people of any ages. Whilst it is recognised that vaccines can cause a flare of eczema symptoms, there is no causal relationship identified between eczema and immunisations in the literature.
For further information on eczema and immunisation please refer to our MVEC page 这里
新的免疫参考页面：疫苗开发和安全
为了增强人们对免疫接种安全性和有效性的信心，MVEC 研究了候选疫苗在注册用于疫苗接种计划之前所采取的步骤。许可后监督计划对于及早发现可能出现的任何意外安全信号也很重要。
要了解更多信息，请访问我们的 MVEC 页面 疫苗开发和安全
New immunisation reference page: Live-attenuated vaccines in patients receiving regular red blood cell transfusions
Patients receiving regular red blood cell transfusions to treat chronic medical conditions such as transfusion dependent thalassaemia, sickle cell disease, inherited chronic haemolytic anaemias, or inherited bone marrow failure syndromes are often left unprotected from vaccine preventable diseases due to not meeting the required intervals between red blood cell transfusions. Evidence in this space is limited, however specialist advice suggests that immunisation of this patient group with live-attenuated vaccines is safe and recommended. As such, MVEC has created a new reference page outlining the process of immunisation for these patients. Please refer to MVEC：接受定期红细胞输注的患者的减毒活疫苗 了解更多信息。